Table 3 Association between MGB-2 protein expression and clinicopathological parameters.
| Â | Â | MGB-2 protein expression | ||
|---|---|---|---|---|
|  | n | score = 0 | score ≥ 1 | P* |
| Â | Â | n (%) | n (%) | Â |
Total | 106 | 64 (60.4) | 42 (39.6) | Â |
Age at diagnosis (y) | Â | Â | Â | Â |
   ≤ 40 | 12 | 6 (50.0) | 6 (50.0) |  |
   > 40 | 94 | 58 (61.7) | 36 (38.3) |  |
| Â | Â | Â | Â | 0.535 |
Histological type | Â | Â | Â | Â |
   endometrioid | 19 | 4 (21.1) | 15 (78.9) |  |
   clear-cell | 11 | 4 (36.4) | 7 (63.6) |  |
   undifferentiated | 5 | 4 (80.0) | 1 (20.0) |  |
   serous-pap.met. | 22 | 19 (86.4) | 3 (13.6) |  |
   mixed | 14 | 6 (42.9) | 8 (57.1) |  |
   mucinous | 3 | 2 (66.7) | 1 (33.3) |  |
   serous-papillary | 32 | 25 (78.1) | 7 (21.9) |  |
| Â | Â | Â | Â | <0.001 |
FIGO stage | Â | Â | Â | Â |
   ≤ IIB | 25 | 7 (28.0) | 18 (72.0) |  |
   > IIB | 81 | 57 (70.4) | 24 (29.6) |  |
| Â | Â | Â | Â | <0.001 |
Histological grade | Â | Â | Â | Â |
   G1 | 7 | 2 (28.6) | 5 (71.4) |  |
   G2 | 13 | 6 (46.2) | 7 (53.8) |  |
   G3 | 86 | 56 (65.1) | 30 (34.9) |  |
| Â | Â | Â | Â | 0.092 |
Residual tumor (TR), cm | Â | Â | Â | Â |
   TR = 0 | 42 | 18 (42.9) | 24 (57.1) |  |
   TR ≥ 0.5 | 64 | 46 (71.9) | 18 (28.1) |  |
| Â | Â | Â | Â | 0.004 |
Ascites | Â | Â | Â | Â |
   no | 44 | 20 (45.5) | 24 (54.5) |  |
   yes | 62 | 44 (71.0) | 18 (29.0) |  |
| Â | Â | Â | Â | 0.010 |
Lymph nodal involvement | Â | Â | Â | Â |
   negative | 53 | 27 (50.9) | 26 (49.1) |  |
   positive | 28 | 21 (75.0) | 7 (25.0) |  |
   missing | 25 | 16 (64.0) | 9 (36.0) |  |
| Â | Â | Â | Â | 0.056 |
Preoperatory CA125 level | Â | Â | Â | Â |
   < Threshold** | 11 | 4 (36.4) | 7 (63.6) |  |
   ≥ Threshold** | 92 | 58 (63.0) | 34 (37.0) |  |
   missing | 3 | 2 (66.7) | 1 (33.3) |  |
| Â | Â | Â | Â | 0.205 |